Should You Buy Intel Stock as Its Foundry Turnaround Takes Shape?

Intel shares have risen more than 220% in 2026 as Q2 revenue increased 25% year over year to more than $16 billion and gross margin expanded 1,290bps to 40.4%. Intel Foundry revenue grew 31% to nearly $6 billion, although the segment still lost $2.1 billion and generated only $293 million from external customers. The 14A node, targeted for risk production in 2027 and volume production in 2028, is central to winning major foundry customers and challenging TSMC, but Intel's forward P/E above 60 and share price above the roughly $116 consensus target leave limited room for execution setbacks.

Analysis

INTC’s rerating now requires a shift from a cyclical CPU recovery to credible third-party foundry economics. Internal wafer revenue does not validate external demand or foundry competitiveness; the key underwriting variable is a binding anchor-customer commitment with meaningful take-or-pay capacity, not management commentary on customer discussions. Until then, the foundry loss base and continued build-out imply that dilution, subsidies, and debt-financed capex remain more relevant to equity value than reported segment revenue.

The near-term setup into Oct. 22 is asymmetric after the sharp move: a solid quarter may be largely priced in, while any weaker gross-margin trajectory, muted external-foundry bookings, or incremental capital requirement could trigger material multiple compression. Over the next 1-3 months, TSM is the cleaner relative beneficiary if prospective customers require leading-edge capacity before 2028; customers cannot wait for an unproven node, and dual-sourcing rhetoric may translate into TSM capacity reservations rather than immediate Intel volume.

The 6-18 month structural upside case for INTC is real only if it converts 14A technical progress into customer-funded utilization. A successful anchor win could reduce perceived terminal underutilization and justify a substantial valuation reset; conversely, a delay or weak yield profile would strand capital and reinforce TSM’s scale advantage. Consensus appears too focused on the node roadmap and insufficiently focused on the commercial terms, customer concentration, yield ramp, and required return on the incremental fabrication asset base.

Key Decisions for Investors

• Do not add directional INTC ahead of Oct. 22 after the rerating; treat an earnings-driven pullback as actionable only if gross-margin guidance holds and management discloses externally verifiable foundry commitments. Thesis fails if guidance implies renewed margin erosion or incremental equity financing within the next 12 months.
• Initiate a 3-6 month relative-value position: long TSM / short INTC, sized beta-neutral. The trade captures TSM’s nearer-term leading-edge demand and INTC’s execution/capex risk; reassess or cover if INTC announces a named, binding 14A anchor customer with material capacity economics.
• For long-only exposure, use INTC only as a milestone trade rather than a core position: add after evidence of customer deposits, take-or-pay agreements, or disclosed external-wafer backlog. A credible contract is more important than a beat on quarterly CPU revenue.
• Monitor Intel’s next filing for capex, free-cash-flow burn, debt maturities, subsidy cash timing, and share count. Any widening between foundry operating losses and external revenue is a warning that internal accounting revenue is masking poor asset utilization.
• Watch TSM commentary on advanced-node capacity allocation and customer demand at its next results. Strong allocation pressure or accelerated overseas capacity commitments strengthens the long TSM leg; broad AI/datacenter demand normalization would weaken both sides and warrants reducing gross exposure.